BIOENGINEER

Chest X-rays and sputum scores flag who may fail shortened all-oral MDR-TB therapy

A prospective cohort study in Lesotho shows that baseline chest radiographic features and sputum smear grades can identify ...
BioSpace

Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresec…

Combination achieved mOS of 23.8 months in patients with unresectable or metastatic HCC; FORT LEE, N.J., Oct. 14, 2026 (GLOBE ...

Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or ...

Combination achieved mOS of 23.8 months in patients with unresectable or metastatic HCCFORT LEE, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Elevar ...

ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation …

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline in CST ...